Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00054184 · ClinicalTrials.gov registry record · Phase 3
Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by CTI BioPharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 350
- Enrollment target
NCT00054184: Clinical Trial Phase 3 study, sponsored by CTI BioPharma.
NCT00054184 is a Phase 3 study that was terminated before completion, run by CTI BioPharma. The registered enrollment target is 350 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00054184, a Phase 3 study, was terminated before completion, sponsored by CTI BioPharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 350 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether polyglutamate paclitaxel is more effective than docetaxel in treating non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of polyglutamate paclitaxel with that of docetaxel in treating patients who have progressive non-small cell lung cancer.
Interventions
- DRUG docetaxel
- DRUG paclitaxel poliglumex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2003-01 |
| Est. Completion | 2004-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00054184
The ClinicalTrials.gov registry entry for NCT00054184 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CTI BioPharma, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which docetaxel is the first listed.
NCT00054184 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00054184 about?
NCT00054184 is a clinical study titled "Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether polyglutamate paclitaxel is more effective than docetaxel in treating non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the ef...
What is the current status of trial NCT00054184?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 350 participants. The study started on 2003-01. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00054184?
The interventions under investigation include: docetaxel (DRUG), paclitaxel poliglumex (DRUG).
Who is sponsoring clinical trial NCT00054184?
This trial is sponsored by CTI BioPharma, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.